Lupus
2 years ago
Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF
2 years ago
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful.
@RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
2 years ago
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
2 years ago
#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
2 years ago
Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI
2 years ago
Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB
2 years ago
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
2 years ago
Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
2 years ago
Excllent plenary, medication copay modifies treatment adherence in SLE
>$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%)
Easy to imagine that all our innovation cannot overcome access & barriers
Should be priority to fix
#ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy